Dr. Galant received her PhD in medical biophysics from the University of Toronto. She provides expertise in antibody design, immunotherapy, and biochemical immuno-characterization. Dr. Galant was the winner of the inaugural Ted Rogers Centre for Heart Research ECHO 2019 $250,000 pitch competition. She is the recipient of numerous academic fellowships and has co-authored over 15 publications in research areas ranging from chemical informatics to immunotherapy drug development.
Dr. Galant received her PhD from the University of Toronto, where her work helped lead to the development of misTTR, an antibody for the potential treatment of ATTR Amyloidosis, that has since been humanized and entering Phase 2/3 clinical trials. Previous to her work at the University of Toronto, Dr. Galant was the on-site coordinator for the chemical research abroad program and a research associate at the University of Szeged in Hungary.
Fun Fact: Dr. Galant is an avid pinball machine enthusiast and passionate member of the Pinside community
Dr. Sun received his PhD in medical biophysics from the University of Toronto. He provides expertise in neurogenerative protein manipulation and target engagement assays. He leads both antibody design and the development of antibody-mediated immunotherapeutic-mediated clearance assays.
Dr. Sun was the winner of the inaugural Ted Rogers Centre for Heart Research ECHO 2019 $250,000 pitch competition. Dr. Sun was also awarded $165,000 by Brain Canada for his work on ALS. Dr. Sun’s ALS research provided new insights into the formation of TDP-43 protein assemblies in the molecular mechanisms of amyotrophic lateral sclerosis and frontotemporal dementia as his PhD thesis. Dr. Sun also holds an MSc in biochemistry from the University of Toronto.
Fun Fact: Dr. Sun is a connoisseur of rare and fine single malt scotch from Islay
Dr. Rossi is the Co-Founder of Moderna, and the founding CEO of Convelo Therapeutics. As a serial biotech entrepreneur and renowned stem cell scientist, his efforts in the development of cutting-edge technologies and novel therapeutic strategies are at the forefront of regenerative medicine and biotechnology. Time magazine cited Dr. Rossi’s discovery of modified-mRNA reprogramming as one of the top ten medical breakthroughs of 2010. Time magazine also named Dr. Rossi as one of “People Who Mattered” in 2010, and as one of the 100 Most Influential People (Time 100) in 2011.
He was a Professor at Harvard Medical School and Harvard University and investigator at Boston Children’s Hospital where he led an academic team working on stem cell biology and regenerative medicine. Dr. Rossi has received multiple awards including the Pathways to Independence (PI) award from the NIH, a Robertson Investigator award from the New York Stem Cell Foundation, and most recently the 2021 Princess of Asturias Award in Scientific Research. Dr. Rossi earned his MSc from the University of Toronto, his PhD from the University of Helsinki and completed a postdoctoral fellowship at Stanford.
Dr. Angèle Maki is a business development executive with nearly twenty years of deal-making experience spanning small biotech and big pharma. She is currently Senior Vice President and head of business development at ReCode Therapeutics, a leading genetic medicines company.
Prior to ReCode, Angèle held business development roles with increasing responsibility starting at Medarex followed by BMS (which acquired Medarex), Genentech, 23andMe, Merck & Co, and Eli Lilly. During her career, she has successfully led diligence and negotiations on numerous in - and out- licensing transactions, from early-stage research technologies to clinical-stage assets.
Angèle has a Ph.D. in biological chemistry from Stanford University and completed postdoctoral work in molecular biology at The Scripps Research Institute in La Jolla. She completed her B.Sc. in chemistry at the University of Winnipeg in Canada.
Fun Fact: Dr. Maki owns a Tonal exercise machine which she uses for challenging herself to advanced workouts led by ex-NFL players
Mr. Glinter is the Founder and CEO of Pendant Biosciences, formerly Nanoferix, headquartered in Nashville, TN. A successful serial entrepreneur in biotech, Mr. Glinter serves as the current Chairman of the Board for Paradox. He is also the Director of Innovation and Entrepreneurship in the Department of Neurological Surgery and Neuroscience Research at the University of Louisville School of Medicine and an Expert Contributor at the Entrepreneurial Mind.
Concurrently, Mr. Glinter holds a variety of mentorship roles including being a Mentor in Residence at the Wond’ry Center for Innovation and Entrepreneurship at Vanderbilt University, and a Mentor at Life Sciences Tennessee and Jumpstart Foundry. He is also a Master Mentor at the Nashville Entrepreneur Center and at Launch TN. Mr. Glinter founded B&G Holdings to invest in and coach early stage and start up companies. He attended both the University of Maryland College Park and the George Washington University and actively volunteers as a Board Member for a variety of organizations.
Fun Fact: Shawn used to volunteer as a professional clown in children’s hospitals.
Dr. Barry A. Springer, Ph.D., is currently the Principal at Springer Bio-Tech Consulting, LLC, advising early-stage biotechnology companies since 2021. With over 30 years of experience in the industry, he has an accomplished background in small molecule and biologics drug discovery, development, licensing, and technology development.
His career began at DuPont Merck, moving on to be a founding member at 3-Dimensional Pharmaceuticals (3DP). His notable contributions led to the company's acquisition by Johnson & Johnson (J&J). As VP of Enabling Technologies at J&J R&D, he was a member of the leadership team that brought drugs to the clinic, including Invokana.
From 2011 to 2020, Dr. Springer served as VP of Janssen BioTherapeutics, overseeing strategy, operations, and external innovation initiatives. His leadership roles resulted in high-value partnerships, new technologies, and the development of significant drugs such as Rybrevant, Amivantamab for NSCLC, Teclistamab and Talquetamab for multiple myeloma. He earned his Ph.D. in Biochemistry from the University of Illinois and completed his postdoctoral training at U.C. Berkeley.
Fun Fact: Barry is a big Chicago Cubs fan.
Dr. Tiedemann is an Associate Professor of Medicine at University of Toronto and a Clinician-Scientist and Staff Hematologist in Medical Oncology at University Health Network. His clinical and scientific focus remains on novel treatments for multiple myeloma and associated light chain amyloidosis.
Previously, Dr. Tiedemann was a Senior Associate Consultant and Assistant Professor of Medicine at the Mayo Clinic. Prior to that he was a postdoctoral fellow at the Mayo Clinic in Scottsdale Arizona. Dr. Tiedemann was awarded his PhD in Molecular Medicine from the University of Auckland (Australia). Also from the University of Auckland, he received Fellowships in both the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia.
Dr. Ferro is a former Scientific Officer at Novartis and prior to that a Clinical Team Leader at Sanofi Pasteur. He has extensive experience in vaccine development for infectious diseases and was the Head of Internal Medicine at Hospital Militar in Nicaragua.
Dr. Ferro received his Medical Degree from the Pontificia Universidad Javeriana (Bogata Columbia) and specialized in Internal Medicine. He also holds a Diploma in Clinical Epidemiology from the University of Toronto.
Dr. Hadley completed his PhD in Medical Biophysics at the University of Toronto. He subsequently completed a postdoctoral fellowship and became a scientific associate at the University Health Network in Toronto, Canada. Dr. Hadley has spent more than 18 years exploring the world of protein misfolding, from molecular chaperones to amyloidosis. At Paradox, his responsibilities include candidate design and the development of specialized protein misfolding assays to screen Paradox's misfolding-specific antibodies.
Fun fact: Kevin has been to Iceland five times, but only had to dig his rental car out of a snowdrift once.
Dr. Menon completed his PhD in Biochemistry from Hunter College, City University of New York, NY and a postdoctoral fellowship at the University of Maryland, Baltimore. He brings over 9 years of research experience in the identification and characterization of proteins involved in cancer and retinal diseases. As a scientist at Paradox, he is responsible for the biochemical characterization of lead therapeutic drug candidates.
Fun fact: Besides his love for the outdoors, Dr. Menon has a green thumb and takes a highly scientific approach to gardening and indoor hydroponics
Ryan completed his M.Sc. in Immunology at the University of Toronto. He brings two years of experience in cell-based immunoassays and one year as a lab technician where he processed patient samples and managed research databases. At Paradox, Ryan brings insight into the immunological aspects of Paradox’s drug candidates and to developing cell-based in vitro assays.
Fun fact: Ryan very much enjoys listening to video game soundtracks. He recommends giving the Persona 5 soundtrack a listen for some groovy tunes!
.svg)
.svg)
